Direct-to-Biology Approach Delivers a Selective GRP78 Inhibitor Probe
- GRP78 (BiP/HSPA5) is a chaperone in the highly conserved HSP70 family, making isoform-selective inhibitors difficult to design.
- Using a Direct-to-Biology (D2B) strategy — synthesizing and screening compounds without intermediate purification — researchers identified compound 12 as a selective GRP78 inhibitor.
- Compound 12 binds the peptide-binding pocket in GRP78's substrate-binding domain and is selective for GRP78 over other tested HSP70 isoforms.
- It potently and selectively kills A549 lung cancer cells while showing minimal activity in other tested lung cancer cell lines.
- Cellular thermal shift assay (CETSA) confirmed cellular target engagement, and compound 12 modulates GRP78-linked unfolded protein response (UPR) stress signaling.
- The authors present compound 12 as a chemical probe for studying GRP78 biology and a starting point for GRP78-targeted therapeutics.
Substrate-binding domain, not the ATPase pocket — that's the harder but more selective play, since most HSP70-family programs chase the nucleotide site and inherit its cross-reactivity problem. Getting selectivity for GRP78 over other HSP70 isoforms out of a peptide-binding groove is a real medicinal chemistry win; those pockets are shallow and promiscuous by design. What I'd want to see next: the SAR trail from D2B — crude-plate hits jumping straight to CETSA-confirmed engagement is fast, but I'd want a clean resynthesis and dose-response before trusting potency off unpurified reactions. Still, as a probe-grade starting point with A549-selective killing, compound 12 is a legitimate template for follow-on optimization, not another ATPase-site me-too.
Development of Isoform-Selective GRP78 Inhibitors from a Direct-to-Biology Strategy ↗